Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andres J Yarur

Showing results (1-10 of 71) with videos related to

Pageof 8
Sort By:
Journal of Crohn'S & Colitis|February 9, 2022
Intestinal Tissue Levels of Anti-Tumour Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases: Are We Looking in The Right Place at The Right Time?Andres J Yarur
The American Journal of Gastroenterology|November 30, 2023
Response to Bourgonje and MianAndres J Yarur
Gastroenterology|November 12, 2023
ReplyAndres J Yarur, Parakkal Deepak
Current Opinion in Gastroenterology|June 28, 2022
Integrating new and emerging therapies into inflammatory bowel disease clinical practiceShaina Sekhri, Andres J Yarur
Journal of Clinical Medicine|October 28, 2023
A Review of Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Combination TherapySanket Patel, Andres J Yarur
Digestive Diseases and Sciences|October 31, 2020
Better Late than Never: Adding Thiopurines After Loss of Response to Infliximab MonotherapyEmily M Villareal, Andres J Yarur
Inflammatory Bowel Diseases|April 23, 2015
Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel DiseasesAndres J Yarur, David T Rubin
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 17, 2014
Back to the beginning: restarting infliximab in inflammatory bowel disease patients with prior loss of responseAndres J Yarur, Maria T Abreu
Inflammatory Bowel Diseases|May 31, 2014
Hepatobiliary manifestations of inflammatory bowel diseaseAndres J Yarur, Frank Czul, Cynthia Levy
Drugs|March 13, 2023
Safety of Janus Kinase Inhibitors in Inflammatory Bowel DiseasesPaulina Núñez, Rodrigo Quera, Andres J Yarur
Pageof 8

Showing results (1-10 of 71) with videos related to

Sort By:
Pageof 8
Journal of Crohn'S & Colitis|February 9, 2022
Intestinal Tissue Levels of Anti-Tumour Necrosis Factor Agents in Patients with Inflammatory Bowel Diseases: Are We Looking in The Right Place at The Right Time?Andres J Yarur
The American Journal of Gastroenterology|November 30, 2023
Response to Bourgonje and MianAndres J Yarur
Gastroenterology|November 12, 2023
ReplyAndres J Yarur, Parakkal Deepak
Current Opinion in Gastroenterology|June 28, 2022
Integrating new and emerging therapies into inflammatory bowel disease clinical practiceShaina Sekhri, Andres J Yarur
Journal of Clinical Medicine|October 28, 2023
A Review of Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Receiving Combination TherapySanket Patel, Andres J Yarur
Digestive Diseases and Sciences|October 31, 2020
Better Late than Never: Adding Thiopurines After Loss of Response to Infliximab MonotherapyEmily M Villareal, Andres J Yarur
Inflammatory Bowel Diseases|April 23, 2015
Therapeutic Drug Monitoring of Anti-tumor Necrosis Factor Agents in Patients with Inflammatory Bowel DiseasesAndres J Yarur, David T Rubin
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 17, 2014
Back to the beginning: restarting infliximab in inflammatory bowel disease patients with prior loss of responseAndres J Yarur, Maria T Abreu
Inflammatory Bowel Diseases|May 31, 2014
Hepatobiliary manifestations of inflammatory bowel diseaseAndres J Yarur, Frank Czul, Cynthia Levy
Drugs|March 13, 2023
Safety of Janus Kinase Inhibitors in Inflammatory Bowel DiseasesPaulina Núñez, Rodrigo Quera, Andres J Yarur
Pageof 8